TY - JOUR
T1 - Metabolomics Identifies a Panel of Diagnostic Biomarkers for Early Human Embryonic Development Arrest
AU - Liu, Yifei
AU - Fan, Xuemei
AU - Pang, Huanhuan
AU - Liu, Saiya
AU - Wang, Bohong
AU - Wang, Chunmei
AU - Yan, Qingya
AU - Song, Wenping
AU - Hu, Zeping
AU - Liu, Qingfei
AU - Shi, Yun
N1 - Funding Information:
This study was supported by the National Natural Science Foundation of China (no. 81202717).
Publisher Copyright:
© 2023 American Chemical Society.
PY - 2023/4/7
Y1 - 2023/4/7
N2 - Early embryonic development arrest (EEDA) is a unique form of early spontaneous abortion in pregnant women, which is previously suggested to be associated with metabolic abnormalities. Noninvasive biomarkers would significantly improve its diagnosis and clinical outcome. Here, we performed a targeted metabolomics study in plasma from EEDA patients (n = 27) and normal pregnant women (NPW, n = 27) using liquid chromatography coupled with mass spectrometry (LC-MS) to identify potential diagnostic marker metabolites. Our results showed significantly different plasma metabolic profiles between EEDA patients and NPW. Particularly, EEDA patients showed significant alterations in amino acid, carbohydrate, and vitamin metabolism, which were characterized by 21 significantly increased metabolites and five decreased metabolites in plasma. Further receiver operating characteristic analysis showed that an optimal combination of S-methyl-5′-thioadenosine, kynurenine, leucine, and malate could be used as a panel of metabolites for EEDA diagnosis. The area under the curve of the metabolite panel was 0.941, suggesting a better performance than any single metabolite for the diagnosis of EEDA. In summary, our study identifies a panel of differential metabolites in plasma that could act as potential biomarkers for the diagnosis of EEDA in clinical settings.
AB - Early embryonic development arrest (EEDA) is a unique form of early spontaneous abortion in pregnant women, which is previously suggested to be associated with metabolic abnormalities. Noninvasive biomarkers would significantly improve its diagnosis and clinical outcome. Here, we performed a targeted metabolomics study in plasma from EEDA patients (n = 27) and normal pregnant women (NPW, n = 27) using liquid chromatography coupled with mass spectrometry (LC-MS) to identify potential diagnostic marker metabolites. Our results showed significantly different plasma metabolic profiles between EEDA patients and NPW. Particularly, EEDA patients showed significant alterations in amino acid, carbohydrate, and vitamin metabolism, which were characterized by 21 significantly increased metabolites and five decreased metabolites in plasma. Further receiver operating characteristic analysis showed that an optimal combination of S-methyl-5′-thioadenosine, kynurenine, leucine, and malate could be used as a panel of metabolites for EEDA diagnosis. The area under the curve of the metabolite panel was 0.941, suggesting a better performance than any single metabolite for the diagnosis of EEDA. In summary, our study identifies a panel of differential metabolites in plasma that could act as potential biomarkers for the diagnosis of EEDA in clinical settings.
KW - diagnosis
KW - early embryo development arrest
KW - potential biomarkers
KW - targeted metabolomics
UR - http://www.scopus.com/inward/record.url?scp=85151373293&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85151373293&partnerID=8YFLogxK
U2 - 10.1021/acs.jproteome.2c00816
DO - 10.1021/acs.jproteome.2c00816
M3 - Article
C2 - 36975128
AN - SCOPUS:85151373293
SN - 1535-3893
VL - 22
SP - 1280
EP - 1286
JO - Journal of Proteome Research
JF - Journal of Proteome Research
IS - 4
ER -